Tandem Diabetes Care, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 195.92 million compared to USD 200.26 million a year ago. Net loss was USD 35.78 million compared to USD 15.06 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.55 compared to USD 0.24 a year ago.
For the six months, sales was USD 365.3 million compared to USD 376.17 million a year ago. Net loss was USD 159.65 million compared to USD 29.77 million a year ago. Basic loss per share from continuing operations was USD 2.47 compared to USD 0.47 a year ago. Diluted loss per share from continuing operations was USD 2.47 compared to USD 0.47 a year ago.